Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02598596 · ClinicalTrials.gov registry record · Phase 2
Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect
A Phase 2 study, sponsored by Ampel BioSolutions.
- Completed
- Registry status
- Phase 2
- Development phase
- 132
- Enrollment target
NCT02598596: Completed Phase 2 study, sponsored by Ampel BioSolutions.
NCT02598596 is a Phase 2 study that has completed, run by Ampel BioSolutions. The registered enrollment target is 132 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02598596, a Phase 2 study, has completed, sponsored by Ampel BioSolutions.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 132 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of a high zone tolerizing regimen of pegloticase on clinical outcome, as defined by an serum uric acid level \<6 mg/dL, in patients with chronic, refractory gout.
Primary Outcome
Determine response rate; the last 3 consecutive levels of SUA must be \<6 mg/dL
Interventions
- DRUG Azathioprine
- BIOLOGICAL Pegloticase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2015-12 |
| Est. Completion | 2020-04-27 |
| Phase | Phase 2 |
What the finished NCT02598596 record still lists
NCT02598596 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Azathioprine is the first listed.
NCT02598596 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02598596 about?
NCT02598596 is a clinical study titled "Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect". The purpose of this study is to evaluate the effect of a high zone tolerizing regimen of pegloticase on clinical outcome, as defined by an serum uric acid level \<6 mg/dL, in patients with chronic, refractory gout.
What is the current status of trial NCT02598596?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 132 participants. The study started on 2015-12. Estimated completion is 2020-04-27.
What interventions are being tested in trial NCT02598596?
The interventions under investigation include: Azathioprine (DRUG), Pegloticase (BIOLOGICAL).
Who is sponsoring clinical trial NCT02598596?
This trial is sponsored by Ampel BioSolutions, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02598596's enrollment target sits among peer trials
132 539th of 2000 higher than 1,460 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04002947 · 132 participants · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia